TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01218854

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Needle angle measurement
Description: The tool for measuring the needle angles will be an FDA-approved EM tracking system. At no time will the needle enter tissue that it wouldn t have otherwise entered as neither system will be used to perform the biopsies at this time.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Needle angle measurement
Description: The tool for measuring the needle angles will be an FDA-approved EM tracking system. At no time will the needle enter tissue that it wouldn t have otherwise entered as neither system will be used to perform the biopsies at this time.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Needle angle measurement
Description: The tool for measuring the needle angles will be an FDA-approved EM tracking system. At no time will the needle enter tissue that it wouldn t have otherwise entered as neither system will be used to perform the biopsies at this time.
Study: NCT00843882

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epoetin Alfa
Description: Given SC

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study: NCT04290806

Intervention type: OTHER
Intervention: Routine care as per site standard
Description: Physician's choice according to patient's needs. Routine care as per site standard.

Intervention type: OTHER
Intervention: Routine care as per site standard
Description: Physician's choice according to patient's needs. Routine care as per site standard.

Intervention type: OTHER
Intervention: Routine care as per site standard
Description: Physician's choice according to patient's needs. Routine care as per site standard.

Intervention type: OTHER
Intervention: Routine care as per site standard
Description: Physician's choice according to patient's needs. Routine care as per site standard.
Study: NCT03173235

Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma level of vitamin D
Description: messurement of plasma level of vitamin D

Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma level of vitamin D
Description: messurement of plasma level of vitamin D
Study: NCT03406351

Intervention type: OTHER
Intervention: Observational
Description: Observational deep phenotyping physiological readouts

Intervention type: OTHER
Intervention: Observational
Description: Observational deep phenotyping physiological readouts
Study: NCT02074293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Botox subdermally
Description: Adverse Reactions of Botox (onabotulinumtoxinA) subdermally at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Botox subdermally
Description: Adverse Reactions of Botox (onabotulinumtoxinA) subdermally at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.
Study: NCT00712894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem
Description: Intracoronary Infusion 400-2000ug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verapamil
Description: Intracoronary Infusion 200-1000ug
Study: NCT03094910

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Examination of vibration perception threshold in fingertips
Description: Vibration perception threshold is examined for 7 different frequences. All fingers are examined except for the thumbs.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Examination of vibration perception threshold in fingertips
Description: Vibration perception threshold is examined for 7 different frequences. All fingers are examined except for the thumbs.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Ewing's tests
Description: A battery of tests invented to diagnose the cardiac autonomic neuropathy in diabetics. Heart rate and blood pressure are measured during Valsalva maneuver, deep breathing, active standing and prolonged handgrip.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Ewing's tests
Description: A battery of tests invented to diagnose the cardiac autonomic neuropathy in diabetics. Heart rate and blood pressure are measured during Valsalva maneuver, deep breathing, active standing and prolonged handgrip.
Study: NCT00712894

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitroglycerin
Description: Intracoronary Infusion 200-1000ug
Study: NCT02710084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Intranasal oxytocin
Study: NCT03094910

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Tilt table test
Description: Blood pressure and heart rate are measured continuously while the participant is brought to a 60 degree position and held there for 15 minutes.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Tilt table test
Description: Blood pressure and heart rate are measured continuously while the participant is brought to a 60 degree position and held there for 15 minutes.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Thermography
Description: An infrared thermographic camera is applied to record temperature of the fingers of the participant before and after cooling in 10 degree water for 1 min.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Thermography
Description: An infrared thermographic camera is applied to record temperature of the fingers of the participant before and after cooling in 10 degree water for 1 min.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 123I-MIBG
Description: 123I-MIBG is injected into a vein, and an early and a late scan is performed. Regions Of Interest are selected for the heart and mediastinum, and the ratio as well as well as the Washout Rate can be determined. MIBG is a noradrenaline analogue and the examination is performed to visualize a potential imbalance of the autonomic nervous system of the heart.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood samples
Description: The blood samples will be assayed for hemoglobin, long-term blood sugar, C-reactive protein, sodium, potassium, magnesium, albumin, TSH, vitamin B and D, and ionized calcium.~Patients with suspected Raynaud's disease will be tested for anti-nuclear antibodies (ANA) to screen for underlying rheumatic illness.~Blood samples will also be drawn during tilt table testing and assayed for plasma catecholamines.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood samples
Description: The blood samples will be assayed for hemoglobin, long-term blood sugar, C-reactive protein, sodium, potassium, magnesium, albumin, TSH, vitamin B and D, and ionized calcium.~Patients with suspected Raynaud's disease will be tested for anti-nuclear antibodies (ANA) to screen for underlying rheumatic illness.~Blood samples will also be drawn during tilt table testing and assayed for plasma catecholamines.
Study: NCT03901014

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard American diet
Description: Standard American diet with 50% energy from carbohydrate, 30% from fat, and 20% from protein.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very low carbohydrate diet
Description: Ketogenic diet with \<50g carbohydrate, 60-75% energy from fat, and 20% from protein
Study: NCT00493571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gimatecan
Description: Starting dose: 0.6 mg capsules administered orally once daily.
Study: NCT02663596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Patient requiring CRRT and vancomycin that provide consent will be given vancomycin as a continuous infusion by mixing the vancomycin into the CRRT solution(s)
Study: NCT00299156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Starting dose 10 mg (Group 1) or 20 mg (Group 2) as tablets once a day for 5 days in a row and repeated every 4-8 weeks. Each 4-8 week period is a cycle.
Study: NCT03996486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1093884
Description: Drug administered via subcutaneous injections once weekly for 6 weeks (= 6 doses)
Study: NCT02540356

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAX69 Single-Route Arm
Description: Intraperitoneal (IP) only

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAX69 Double-Route Arm
Description: Intravenous (IV) infusion + intraperitoneal (IP) infusion
Study: NCT00198029

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Synvisc (hylan G-F20)
Description: 32 subjects in the pilot study have received 3 1ml injections of Synvisc intraarticular over the course of 3 weeks and then followed for 6 months post injection
Study: NCT00521456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketorolac eye drops
Description: 1 drop twice daily day preop and Days 1-14, and 6 doses on surgery day~Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ketorolac eye drops
Description: 1 drop twice daily day preop and Days 1-14, and 6 doses on surgery day~Placebo
Study: NCT01143025

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 50 mg
Description: Preoperative nebulization of 50 mg of Ropivacaine in the peritoneal cavity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 100 mg
Description: Preoperative nebulization of 100 mg of Ropivacaine in the peritoneal cavity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 150 mg
Description: Preoperative nebulization of 150 mg of Ropivacaine in the peritoneal cavity
Study: NCT04559607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab: 200mg, iv, Q3W

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: TACE if necessary

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE if necessary

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib: 250m, po, QD
Study: NCT02483637

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RejuvenAir
Description: Device: RejuvenAir
Study: NCT04414956

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: AFP-L3
Description: AFP-L3 will be tested using serum sample every 6 months.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: AFP
Description: AFP will be tested using serum sample every 6 months.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PIVKA-II
Description: PIVKA-II will be tested using serum sample every 6 months.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Sonography
Description: Sonography will be tested by experts every 6 months.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: CT
Description: Contrast-enhanced CT will be tested annually.
Study: NCT02651636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: myo-inositol,alpha-lipoic acid and folic acid
Study: NCT00646945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50% Oxygen/50% Nitrous oxide premix (Kalinox 170 bar)
Description: gas flow between 4 to 15 L/min

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 50% Oxygen/50% Nitrogen premix
Description: gas flow between 4 to 15 L/min
Study: NCT04337996

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: COVID-19 diagnostic test
Description: COVID-19 diagnostic tests performed at day 1 (antigen in blood serum, SARS-Cov2 PCR, antibodies in blood serum) COVID-19 diagnostic test performed at day 21 (antibodies in blood serum)
Study: NCT01924390

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mineralized freeze-dried bone allograft alone

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combination of Mineralized and demineralized freeze-dried bone allograft alone
Study: NCT02710084

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo
Study: NCT03450577

Intervention type: PROCEDURE
Intervention: PCI of bifurcation lesions
Description: Different approaches for treatment of bifurcation coronary artery disease.
Study: NCT03905304

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Medytoxin
Description: Intramuscular injection up to 300U.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Botox
Description: Intramuscular injection up to 300U.
Study: NCT01575548

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib Hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study: NCT04079686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephazolin
Description: Patients undergoing reduction mammaplasty will receive 1g of cephazolin intravenously anesthetic induction and postoperatively every 6 hours, for 24 hours.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile saline
Description: Patients undergoing reduction mammaplasty will receive 1g of cephazolin intravenously anesthetic induction and intravenous sterile saline postoperatively, every 6 hours, for 24 hours.
Study: NCT01575548

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03972930

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiotherapy
Description: Hypofractionated radiation is delivered using highly conformal technique, allowing for a high dose of radiation to be delivered precisely.
Study: NCT03684980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: (Cohort A) will receive MTX 3 g/m2 or (Cohort B) will receive MTX 8 g/m\^2 (Cohort E) will receive MTX ≤ 3.5 g/ m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: (Cohort A) will receive MTX 3 g/m2 or (Cohort B) will receive MTX 8 g/m\^2 (Cohort E) will receive MTX ≤ 3.5 g/ m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: (Cohort A) will receive MTX 3 g/m2 or (Cohort B) will receive MTX 8 g/m\^2 (Cohort E) will receive MTX ≤ 3.5 g/ m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: (Cohort A) will receive MTX 3 g/m2 or (Cohort B) will receive MTX 8 g/m\^2 (Cohort E) will receive MTX ≤ 3.5 g/ m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Patients will be treated with rituximab 500 mg/m\^2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Patients will be treated with rituximab 500 mg/m\^2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Patients will be treated with rituximab 500 mg/m\^2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin
Description: Patients will also receive standard of care leucovorin rescue starting at least 24 hours after MTX and 2 hours after Voraxaze. Cycles will be 14 days long.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucarpidase
Description: Glucarpidase 2000 units. Arm E 1000 units.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucarpidase
Description: Glucarpidase 2000 units. Arm E 1000 units.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucarpidase
Description: Glucarpidase 2000 units. Arm E 1000 units.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucarpidase
Description: Glucarpidase 2000 units. Arm E 1000 units.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucarpidase
Description: Glucarpidase 2000 units. Arm E 1000 units.
Study: NCT01635374

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Per-Oral Endoscopic Esophagomyotomy
Description: In this procedure, performed in the operating room under general anesthesia, a flexible endoscope is passed into the esophagus, a mucosal flap and a submucosal tunnel is created. This tunnel extends onto the stomach. The inner circular muscle layer of the lower esophagus and sphincter (LES) is identified and a myotomy is started 3-4cm distal to the mucosal flap and carried all the way onto the stomach. The mucosal opening is then closed with standard endoscopic clips. Patients will be admitted to the hospital and a gastrograffin esophagram will be performed on post-op day 2 to rule out esophageal leak. A standardized symptom checklist will be used to assess patient's prior to hospital discharge and on post-op days 4 and 7. All patient will have a 2 week post-op appointment.
Study: NCT00921583

Intervention type: DEVICE
Intervention: Long-term examination
Description: Follow-up dental implants 20 year in function
Study: NCT00472745

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss
Description: Weight loss participants will consume a reduced calorie diet based on their individual caloric needs to lose 1.5-2 lbs/week, and will attend regular counseling sessions (for about 45 minutes each) with a dietitian for 6 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Maintenance
Description: Diet for weight maintenance for 6 months
Study: NCT02637687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Larotrectinib (Vitrakvi, BAY2757556)
Description: BAY2757556 will be administered orally as capsule or in liquid form over continuous 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Larotrectinib (Vitrakvi, BAY2757556)
Description: BAY2757556 will be administered orally as capsule or in liquid form over continuous 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Larotrectinib (Vitrakvi, BAY2757556)
Description: BAY2757556 will be administered orally as capsule or in liquid form over continuous 28-day cycles.
Study: NCT04878939

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Power chain used for anterior segment retraction
Description: Elastomeric chain rendering 160 g/side extending between mini-screw implant and a hook crimped on 0.017- by 0.025-inch stainless steel wire distal to the lateral incisor.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: T-loop fabricated to perform anterior segment retraction
Description: In the frictionless group, anterior segment retraction was done using closing T-loops fabricated from 0.017- by 0.025-inch titanium molybdenum alloy (TMA) wire rendering comparable retraction force.
Study: NCT02590991

Intervention type: OTHER
Intervention: Prebiotics
Description: To study the long term effect of supplementation in early life
Study: NCT03385473

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacogenomic index
Description: All patients will have a blood sample drawn at randomization visits for PG analysis. For patients in the PA arm, the sample will be processed immediately to obtain the PG results and the subsequent index within 10 days. As soon as the results are available, the project team will contact the attending physician to propose the dosing adequation according to the pharmacogenomic index. PG analysis will be performed once for each patient.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic drug monitoring
Description: The patients included in the Pharmacological Adequation arm will have a TDM according to this schedule: day +14 (±3), +28 (±3), and +168 (±3). If there is an abnormal value (out of the therapeutic range), we will proceed to adjust the prescription.
Study: NCT03562806

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/MR image acquisition
Description: Acquisition of PET and MR sequences on SIGNA PET/MR device.
Study: NCT04117607

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 5% Dextrose Injection, USP, a sterile, nonpyrogenic solution of dextrose in water for injection. The solution has the osmolarity of 252 mOsmol/L, which is slightly hypotonic. This solution contains no bacteriostat, antimicrobial agent or added buffer.
Study: NCT03898960

Intervention type: DEVICE
Intervention: NIMBUS Device
Description: NIMBUS Geometric Clot Extractor
Study: NCT02590991

Intervention type: OTHER
Intervention: Prebiotics & Probiotics
Description: To study the long term effect of supplementation in early life
Study: NCT01630018

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: 1.5mg/m2 IV days 1,2,3,4,5 of each 21day cycle until 6cycle or disease progression